| P2093 | author name string | B. K. Park | |
| | S. Madden | |
| | V. Spaldin | |
| P2860 | cites work | Evaluation of HP 029 (Velnacrine Maleate) in Alzheimer's Diseasea | Q33296510 |
| | Identification of the urinary metabolites of tacrine in the rat. | Q33509581 |
| | The effect of enzyme inhibition on the metabolism and activation of tacrine by human liver microsomes | Q34346464 |
| | Steady-state pharmacokinetics of tacrine in patients with Alzheimer's disease | Q34636158 |
| | Clinical pharmacokinetics of intravenous and oral 9-amino-1,2,3,4-tetrahydroacridine, tacrine | Q34648272 |
| | Pharmacokinetics of tacrine hydrochloride in Alzheimer's disease | Q34669866 |
| | Serum concentrations of tacrine hydrochloride predict its adverse effects in Alzheimer's disease | Q34731347 |
| | Tacrine (tetrahydroaminoacridine; THA) and lecithin in senile dementia of the Alzheimer type: a multicentre trial. Groupe Français d'Etude de la Tetrahydroaminoacridine | Q35168053 |
| | The human hepatic cytochromes P450 involved in drug metabolism | Q36258518 |
| | Pharmacodynamic and early clinical studies with velnacrine | Q36744684 |
| | THA--a review of the literature and its use in treatment of five overdose patients | Q40287766 |
| | Tacrine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in Alzheimer's disease | Q40392124 |
| | Open trial of tacrine therapy in 70 HIV-infected patients. | Q41893410 |
| | Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease | Q42603612 |
| | Measurements of tacrine and monoamines in brain by in vivo microdialysis argue against release of monoamines by tacrine at therapeutic doses | Q42713800 |
| | Pharmacokinetics of tetrahydroaminoacridine: relations to clinical and biochemical effects in Alzheimer patients | Q43852948 |
| | Comparison of the chromatographic characteristics of metabolites of tacrine hydrochloride in human serum and urine with those of in vitro metabolic products from hepatic microsomes | Q44091007 |
| | A controlled trial of tacrine in Alzheimer's disease. The Tacrine Study Group | Q44110810 |
| | Distribution of tacrine across the blood-brain barrier in awake, freely moving rats using in vivo microdialysis sampling | Q48360983 |
| | A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. The Tacrine Collaborative Study Group | Q48418557 |
| | A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. The Tacrine Study Group. | Q52026922 |
| | Tetrahydroaminoacridine-lecithin combination treatment in patients with intermediate-stage Alzheimer's disease. Results of a Canadian double-blind, crossover, multicenter study. | Q52057810 |
| | Velnacrine in Alzheimer's Disease : An Initial Appraisal of its Clinical Potential. | Q52058562 |
| | Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type. | Q52259713 |
| | Disposition of propranolol. V. Drug accumulation and steady-state concentrations during chronic oral administration in man. | Q52939660 |
| | Tacrine for treating Alzheimer's disease | Q53179456 |
| | Alzheimer's drug trial put on hold. | Q53192415 |
| | Tacrine for Alzheimer's disease. Which patient, what dose? | Q53206871 |
| | Tacrine in Alzheimer's disease | Q56763713 |
| | The Prevalence of Dementia in Europe: A Collaborative Study of 1980–1990 Findings | Q57782178 |
| | Blocking Effect of Tetrahydroaminacrin on a New Psychotomimetic Agent | Q58959978 |
| | Letter: Replacement drug for edrophonium bromide | Q67358296 |
| | Treatment for Alzheimer's disease? | Q67522232 |
| | Determination of tacrine hydrochloride in human serum by chloroform extraction, reversed-phase high-performance liquid chromatography and fluorimetric detection | Q68049023 |
| | Characterisation of theophylline metabolism by human liver microsomes. Inhibition and immunochemical studies | Q68142727 |
| | Hepatotoxicity of tetrahydroaminoacridine in isolated rat hepatocytes: effect of glutathione and vitamin E | Q68431139 |
| | Tacrine and lecithin in Alzheimer's disease | Q68780451 |
| | Cigarette smoking and theophylline metabolism: effects of phenytoin | Q69208179 |
| | Determination of tacrine and its 1-hydroxy metabolite in plasma using column liquid chromatography with ultraviolet detection | Q69385939 |
| | Quantitative whole-body autoradiographic determination of tacrine tissue distribution in rats following intravenous or oral dose | Q69398829 |
| | Identification of 9-hydroxylamine-1,2,3,4-tetrahydroacridine as a hepatic microsomal metabolite of tacrine by high-performance liquid chromatography and electrochemistry | Q69613356 |
| | Tetrahydroaminoacridine and Alzheimer's disease | Q69893614 |
| | Stereoselective hydroxylation of tacrine in rats and humans | Q72458240 |
| | Bioactivation and irreversible binding of the cognition activator tacrine using human and rat liver microsomal preparations. Species difference | Q72658526 |
| | An investigation into the formation of stable, protein-reactive and cytotoxic metabolites from tacrine in vitro. Studies with human and rat liver microsomes | Q72870562 |
| | Suxamethonium "extension" by tetrahydroaminacrine | Q79444210 |
| | Some aspects of the pharmacology of morphine with special reference to its antagonism by 5-amino-acridine and other chemically related compounds | Q80641191 |
| | Treatment of Intractable Pain with Morphine and Tetrahydroaminacrine | Q84946602 |
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pharmacokinetics | Q323936 |
| P304 | page(s) | 449-457 | |
| P577 | publication date | 1995-06-01 | |
| P1433 | published in | Clinical Pharmacokinetics | Q5133788 |
| P1476 | title | Clinical Pharmacokinetics of Tacrine | |
| P478 | volume | 28 | |